These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31963654)

  • 1. Risk Factors Associated with Outcomes of Recombinant Tissue Plasminogen Activator Therapy in Patients with Acute Ischemic Stroke.
    Tseng YJ; Hu RF; Lee ST; Lin YL; Hsu CL; Lin SW; Liou CW; Lee JD; Peng TI; Lee TH
    Int J Environ Res Public Health; 2020 Jan; 17(2):. PubMed ID: 31963654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue plasminogen activator (rt-PA) in acute ischemic stroke: Outcomes associated with ambulation.
    Lawson TR; Brown IE; Westerkam DL; Blackhurst DW; Sternberg S; Leacock R; Nathaniel TI
    Restor Neurol Neurosci; 2015; 33(3):301-8. PubMed ID: 25698111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.
    Yan X; Hu HT; Liu S; Sun YH; Gao X
    Neurol Res; 2015 Apr; 37(4):352-8. PubMed ID: 25297471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant tissue plasminogen activator (rt-PA) utilisation by rural clinicians in acute ischaemic stroke: an audit of current practice and clinical outcomes.
    Williams JM; Navin TJ; Jude MR; Levi CR
    Aust J Rural Health; 2013 Aug; 21(4):203-7. PubMed ID: 24033520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.
    Betts KA; Hurley D; Song J; Sajeev G; Guo J; Du EX; Paschoalin M; Wu EQ
    J Stroke Cerebrovasc Dis; 2017 Sep; 26(9):1996-2003. PubMed ID: 28689999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The correlation between admission blood glucose and intravenous rt-PA-induced arterial recanalization in acute ischemic stroke: a multi-centre TCD study.
    Saqqur M; Shuaib A; Alexandrov AV; Sebastian J; Khan K; Uchino K
    Int J Stroke; 2015 Oct; 10(7):1087-92. PubMed ID: 26332252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In acute ischemic stroke patients with smoking incidence, are more women than men more likely to be included or excluded from thrombolysis therapy?
    Rotimi OR; Ajani IF; Penwell A; Lari S; Walker B; Nathaniel TI
    Womens Health (Lond); 2020; 16():1745506520922760. PubMed ID: 32459136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of metabolic syndrome and obesity on outcomes of acute ischemic stroke patients treated with systemic thrombolysis.
    Bas DF; Ozdemir AO
    J Neurol Sci; 2017 Dec; 383():1-4. PubMed ID: 29246591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favourable renal outcomes after intravenous thrombolytic therapy for acute ischemic stroke: Clinical implication of kidney-brain axis.
    Chang TH; Chiu PF; Tsai CC; Chang CH; Wu CL; Kor CT; Li JR; Kuo CL; Huang CS; Chu CC; Lin CM; Chang CC
    Nephrology (Carlton); 2019 Sep; 24(9):896-903. PubMed ID: 30334303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.
    Al-Khaled M; Matthis C; Eggers J
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):7-11. PubMed ID: 22578915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient refusal of thrombolytic therapy for suspected acute ischemic stroke.
    Vahidy FS; Rahbar MH; Lal AP; Grotta JC; Savitz SI
    Int J Stroke; 2015 Aug; 10(6):882-6. PubMed ID: 23227830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use.
    Lin SY; Tang SC; Tsai LK; Yeh SJ; Hsiao YJ; Chen YW; Chen KH; Yip BS; Shen LJ; Wu FL; Jeng JS
    Eur J Neurol; 2014 Oct; 21(10):1285-91. PubMed ID: 24909847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. US geographic distribution of rt-PA utilization by hospital for acute ischemic stroke.
    Kleindorfer D; Xu Y; Moomaw CJ; Khatri P; Adeoye O; Hornung R
    Stroke; 2009 Nov; 40(11):3580-4. PubMed ID: 19797701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
    Lee SH; Kim BJ; Han MK; Park TH; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Nah HW; Lee J; Lee SJ; Ko Y; Kim JG; Park JM; Kang K; Cho YJ; Hong KS; Choi JC; Kim JT; Choi K; Kim DE; Ryu WS; Kim WJ; Shin DI; Yeo M; Lee J; Lee JS; Gorelick PB; Bae HJ
    Int J Stroke; 2016 Oct; 11(7):783-90. PubMed ID: 27312681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preprocedure Intravenous Recombinant Tissue Plasminogen Activator and Risk of Distal Embolization with Thrombectomy in Acute Ischemic Stroke.
    Qureshi AI; Asif A; Aytac E; Liaqat J; Gurkas E; Lobanova I; Saeed O; Ahsan H; Siddiq F; Gomez CR; French BR
    J Stroke Cerebrovasc Dis; 2019 Dec; 28(12):104362. PubMed ID: 31562039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
    Schwammenthal Y; Drescher MJ; Merzeliak O; Tsabari R; Bruk B; Feibel M; Hoffman C; Bakon M; Rotstein Z; Chapman J; Tanne D
    Isr Med Assoc J; 2004 Feb; 6(2):70-4. PubMed ID: 14986460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with the administration of tissue plasminogen activator for acute ischemic stroke.
    Kunisawa S; Kobayashi D; Lee J; Otsubo T; Ikai H; Yokota C; Minematsu K; Imanaka Y
    J Stroke Cerebrovasc Dis; 2014 Apr; 23(4):724-31. PubMed ID: 23910512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to guidelines by emergency medical services during transport of stroke patients receiving intravenous thrombolytic infusion.
    Asaithambi G; Chaudhry SA; Hassan AE; Rodriguez GJ; Suri MF; Qureshi AI
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):e42-5. PubMed ID: 22572162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed Dose IV rt-PA and Clinical Outcome in Ischemic Stroke Patients With Body Weight >100 kg: Pooled Data From 3 Randomized Clinical Trials.
    Majidi S; Leon Guerrero CR; Burger KM; Sigounas D; Olan WJ; Qureshi AI
    J Stroke Cerebrovasc Dis; 2018 Oct; 27(10):2843-2848. PubMed ID: 30076113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.